Origin Bio Analysis: $15M Raised
What is Origin Bio?
Origin Bio develops AI technology to enhance the safety of cell therapies by integrating generative design and functional prediction of regulatory DNA. Their approach involves creating synthetic switches and dials that allow for precise programming of gene expression. The company is supported by a team from prestigious institutions and backed by Y Combinator and notable investors.
Location
San Francisco, United States
Employees
1-10
Founded
2025
Industry
Healthcare, Drug Discovery And Delivery
Functional Type
AI Research
YC Batch
W26
YC Partner
Ankit Gupta
How much Origin Bio raised
Funding - $15.0M
Who are the founders of Origin Bio
YR
Yash Rathod
CEO
Product Description
Origin Bio specializes in developing AI technology aimed at enhancing the safety of cell therapies. Their primary product is the Axis multifunctional DNA model, which integrates generative design and functional prediction of regulatory DNA. This model allows for the creation of synthetic switches and dials that enable precise programming of gene expression, offering unprecedented control over cellular functions.
Key features of the Axis model include:
- Generative Design: Facilitates the creation of custom DNA sequences tailored for specific therapeutic applications.
- Functional Prediction: Provides insights into how designed DNA will behave in biological systems, improving the reliability of cell therapies.
- Precision Programming: Allows researchers to finely tune gene expression, which is crucial for the efficacy and safety of cell therapies.
The benefits of these offerings are significant for biotechnology researchers and genetic engineers, as they enhance the ability to develop safer and more effective cell therapies, ultimately contributing to advancements in medical treatments.
See something that needs updating? Suggest edits to this profile.